
ICLR
ICON PLC
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
188.045
Open
187.740
VWAP
--
Vol
355.73K
Mkt Cap
14.75B
Low
183.590
Amount
--
EV/EBITDA(TTM)
11.46
Total Shares
82.78M
EV
17.77B
EV/OCF(TTM)
15.38
P/S(TTM)
1.91
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
2.02B
+0.82%
3.422
+7.27%
2.02B
-1.19%
3.529
+2.89%
2.00B
-1.6%
3.334
-0.48%
Estimates Revision
The market is revising Downward the revenue expectations for ICON Public Limited Company (ICLR) for FY2025, with the revenue forecasts being adjusted by -3.14% over the past three months. During the same period, the stock price has changed by 23.72%.
Revenue Estimates for FY2025
Revise Downward

-3.14%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward

-2.73%
In Past 3 Month
Stock Price
Go Up

+23.72%
In Past 3 Month
13 Analyst Rating

-12.20% Downside
Wall Street analysts forecast ICLR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICLR is 162.20 USD with a low forecast of 144.00 USD and a high forecast of 187.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
5 Hold
0 Sell
Moderate Buy

-12.20% Downside
Current: 184.730

Low
144.00
Averages
162.20
High
187.00

-12.20% Downside
Current: 184.730

Low
144.00
Averages
162.20
High
187.00
Barclays
Equal Weight
maintain
$155 -> $180
2025-07-25
New
Reason
Barclays
Price Target
$155 -> $180
2025-07-25
New
maintain
Equal Weight
Reason
Barclays raised the firm's price target on Icon to $180 from $155 and keeps an Equal Weight rating on the shares post the Q2 report. The firm sees early signs of stabilization but says one quarter does not make a trend.
UBS
NULL -> Buy
upgrade
$170 -> $240
2025-07-25
New
Reason
UBS
Price Target
$170 -> $240
2025-07-25
New
upgrade
NULL -> Buy
Reason
UBS raised the firm's price target on Icon to $240 from $170 and keeps a Buy rating on the shares.
Mizuho
Outperform
upgrade
$173 -> $225
2025-07-25
New
Reason
Mizuho
Price Target
$173 -> $225
2025-07-25
New
upgrade
Outperform
Reason
Mizuho raised the firm's price target on Icon to $225 from $173 and keeps an Outperform rating on the shares. The company's booking trends were stable in the quarter, much better than feared, the analyst tells investors in a research note. The firm says that when coupled with improved cancelation rates and an improvement in trial delays, there is increased earnings visibility for 2026.
Baird
Neutral -> Outperform
upgrade
$150 -> $224
2025-07-24
New
Reason
Baird
Price Target
$150 -> $224
2025-07-24
New
upgrade
Neutral -> Outperform
Reason
Baird upgraded Icon to Outperform from Neutral with a price target of $224, up from $150. The firm has increased confidence in the shares after the four leading contract research originations posted sequential bookings improvement and stabilized backlog burn. It now sees a "moderate, ratable" recovery into 2026 for Icon.
Leerink
Outperform
upgrade
$195 -> $240
2025-07-24
New
Reason
Leerink
Price Target
$195 -> $240
2025-07-24
New
upgrade
Outperform
Reason
Leerink raised the firm's price target on Icon to $240 from $195 and keeps an Outperform rating on the shares. The company reported strong gross bookings wins in the quarter, the analyst tells investors in a research note. The firm sees potential for more volatility amid a choppy market but believes Icon's earnings power is solid.
Evercore ISI
Outperform
maintain
$170 -> $240
2025-07-24
New
Reason
Evercore ISI
Price Target
$170 -> $240
2025-07-24
New
maintain
Outperform
Reason
Evercore ISI raised the firm's price target on Icon to $240 from $170 and keeps an Outperform rating on the shares. The company provided a further set of data points that the cycle is inflecting, and while it may not be all smooth sailing from here, the above-expectations BtB in Q2 as well as revenue improvement should help provide a significant dose of comfort in the improving demand environment, the analyst tells investors in a research note. The firm added that this demand environment seems similarly broad-based to comments earlier this week, benefitting form stable pharma, improved biotech, higher cardio-metabolic, aided as well by Icon's share gains.
See All Ratings
Valuation Metrics
The current forward P/E ratio for ICON PLC (ICLR.O) is 13.75, compared to its 5-year average forward P/E of 19.14. For a more detailed relative valuation and DCF analysis to assess ICON PLC 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued
5Y Average PE
19.14
Current PE
13.75
Overvalued PE
23.14
Undervalued PE
15.14
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
14.09
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
16.96
Undervalued EV/EBITDA
11.22
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
2.42
Current PS
0.00
Overvalued PS
2.95
Undervalued PS
1.89
Financials
Annual
Quarterly
FY2025Q2
YoY :
-4.85%
2.02B
Total Revenue
FY2025Q2
YoY :
-8.35%
258.88M
Operating Profit
FY2025Q2
YoY :
+24.55%
182.97M
Net Income after Tax
FY2025Q2
YoY :
+30.68%
2.30
EPS - Diluted
FY2025Q2
YoY :
-37.51%
113.92M
Free Cash Flow
FY2025Q2
YoY :
+2.22%
22.99
Gross Profit Margin - %
FY2025Q2
YoY :
-13.81%
12.23
FCF Margin - %
FY2025Q2
YoY :
+30.88%
9.07
Net Margin - %
FY2025Q2
YoY :
-0.39%
7.65
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
150.3K
Volume
8
6-9
Months
185.2K
Volume
3
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
6
815.3K
Volume
Months
6-9
17
2.9M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
8.0K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ICLR News & Events
Events Timeline
2025-07-24 (ET)
2025-07-24
12:01:11
Icon rises 17.2%

2025-07-24
10:00:36
Icon rises 19.5%

2025-07-23 (ET)
2025-07-23
16:21:13
Icon sees FY25 adjusted EPS $13.00-$14.00, consensus $13.25

Sign Up For More Events
Sign Up For More Events
News
2.0
07-27BenzingaThermo Fisher, Baker Hughes And IQVIA Holdings Are Among Top 10 Large Cap Gainers Last Week (July 21-July 25): Are The Others In Your Portfolio?
4.0
07-25BenzingaMizuho Maintains Outperform on Icon, Raises Price Target to $225
4.0
07-25BenzingaEvercore ISI Group Maintains Outperform on Icon, Raises Price Target to $240
Sign Up For More News
People Also Watch

BSBR
Banco Santander Brasil SA
4.785
USD
+1.16%

RPM
RPM International Inc
120.770
USD
-0.63%

SUI
Sun Communities Inc
118.150
USD
+0.64%

EQH
Equitable Holdings Inc
52.330
USD
+0.02%

IEX
IDEX Corp
184.150
USD
-0.15%

XPO
XPO Inc
133.900
USD
-1.36%

BALL
Ball Corp
58.740
USD
+0.10%

UTHR
United Therapeutics Corp
301.180
USD
+1.02%

ENTG
Entegris Inc
91.340
USD
-0.72%

TLK
Telkom Indonesia (Persero) Tbk PT
17.450
USD
+0.87%
FAQ

What is ICON PLC (ICLR) stock price today?
The current price of ICLR is 184.73 USD — it has decreased -2.6 % in the last trading day.

What is ICON PLC (ICLR)'s business?

What is the price predicton of ICLR Stock?

What is ICON PLC (ICLR)'s revenue for the last quarter?

What is ICON PLC (ICLR)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for ICON PLC (ICLR)'s fundamentals?

How many employees does ICON PLC (ICLR). have?
